Beau Visser

• Represented SIX-listed Zur Rose Group on the CHF 360 million sale of its Swiss business to Medbase, a Migros subsidiary.

• Advised KSA Group on sustainable financing by a CHF 120 million Green Bond.

• Advised SIX-listed Zur Rose Group AG on the issuance of CHF 95 million convertible bonds and CHF 44 million capital increase through an accelerated book building.

• Structured the first Special Purpose Acquisition Company (SPAC) under Swiss law and advised VT5 Acquisition Company, the first Swiss-listed SPAC, on its initial public offering.

• Advised Occlutech Holding AG on its SEK 450 million private placement of Swedish Depositary Receipts (SDRs).

• Advised Cosmo Pharmaceuticals in connection with exchange offer for all publicly held registered shares of Cassiopea.

• Represented Implantica on its cross-border IPO and listing on Nasdaq First North Premier.

• Advised VIS Finance S.A. and ELM B.V. on the establishment of their FinSA-compliant secured securities programs.

• Advised Implantica AG, a medtech group with operations in the implantable medical device and eHealth markets, in respect of its IPO on Nasdaq First North Premier.

• Advised SIX-listed biopharmaceuticals company Basilea Pharmaceutica on the completion of its repurchase offer for existing convertible bonds due 2022 and the issuance of new convertible bonds due 2027, accompanied by the provision of a stock loan facility and a delta placement of shares. 

View All

• Dutch Bar Association